[Skip to Content]
[Skip to Content Landing]
Article
September 1985

Apomorphine's Antipsychotic Activity

Author Affiliations

Department of Psychiatry The University of Chicago Chicago, IL 60637
Illinois State Psychiatric Institute University of Illinois—Chicago Chicago, IL 60612
Maryland Psychiatric Research Center University of Maryland Baltimore, MD 21228

Arch Gen Psychiatry. 1985;42(9):927. doi:10.1001/archpsyc.1985.01790320099017
Abstract

To the Editor.—  Some controversy has developed recently over the antipsychotic efficacy of apomorphine in schizophrenic psychosis, including an article by Levy et al1 in the Archives.2 It is our opinion that a definitive answer to this question requires a broader experimental approach than that attempted by the investigators in either of these groups. Previously, Corsini and co-workers3,4 reported apomorphine's marked antipsychotic action when given in a dose of 1 mg subcutaneously to a group of unmedicated schizoaffective patients. Tamminga et al,5 in a double-blind placebocontrolled study, showed an equally dramatic effect of a 3-mg subcutaneous dose given to a group of chronic schizophrenic and schizoaffective subjects who were maintained on a neuroleptic regimen.5Those drug trials reporting antipsychotic activity of apomorphine in a controlled design are characterized by at least two features. First, a range of apomorphine doses, including high levels, were used in the

First Page Preview View Large
First page PDF preview
First page PDF preview
×